

Bi Jingquan met US FDA to discuss on promoting innovations under regulatory reform

07 June 2017 | News

Bi Jingquan, Minister of China Food and Drug Administration (CFDA), met with the delegation led by Dr. Theresa Mullin, Director of the Office of Strategic Programs of the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA).



Bi Jingquan, Minister of China Food and Drug Administration (CFDA), met with the delegation led by Dr. Theresa Mullin, Director of the Office of Strategic Programs of the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA).

Bi Jingquan, Minister of China Food and Drug Administration (CFDA), met with the delegation led by Dr. Theresa Mullin, Director of the Office of Strategic Programs of the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA).

The delegation was accompanied by chair of the Management Committee of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).

Both sides exchanged opinions on promoting drug innovation through regulatory reform, China joining ICH etc. Bi Jingquan delivered to Dr. Theresa Mullin a letter of congratulation to convey to the newly appointed FDA Commissioner Scott Gottlieb;

Dr. Scott Gottlieb was sworn in as the 23rd Commissioner of Food and Drugs. Dr. Gottlieb is a physician, medical policy expert, and public health advocate who previously served as the FDA's Deputy Commissioner for Medical and Scientific Affairs and before that, as a senior advisor to the FDA Commissioner.

He also worked on implementation of the Medicare drug benefit as a senior advisor to the Administrator of the Centers for Medicare and Medicaid Services, where he supported policy work on quality improvement and the agency's coverage process, particularly as it related to new medical technologies.

Dr. Theresa Mullin hand over a greeting letter from Scott Gottlieb to Bi Jingquan. CFDA Vice Minister Wu Zhen and relevant directors of CFDA's related departments attended the meeting.